Zevra Therapeutics (ZVRA) Current Assets (2014 - 2026)

Zevra Therapeutics' Current Assets history runs 13 years deep, the most recent figure standing at $230.0 million for Q1 2026.

• Quarterly Current Assets rose 181.92% year-over-year to $230.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $230.0 million (up 181.92% YoY) and the FY2025 annual result came in at $223.0 million, up 159.23% from the prior year.
• Current Assets was $230.0 million for Q1 2026 at Zevra Therapeutics, up from $223.0 million in the prior quarter.
• Across five years, Current Assets topped out at $230.0 million in Q1 2026 and bottomed at $60.9 million in Q2 2024.
• A 5-year average of $123.3 million and a median of $99.4 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets sank 41.13% — and 2025, when it soared 271.71%.
• Zevra Therapeutics' Current Assets stood at $92.8 million in 2022, then declined by 6.35% to $86.9 million in 2023, then retreated by 1.05% to $86.0 million in 2024, then soared by 159.23% to $223.0 million in 2025, then increased by 3.12% to $230.0 million in 2026.
• Business Quant data shows ZVRA's Current Assets at $230.0 million in Q1 2026, $223.0 million in Q4 2025, and $225.1 million in Q3 2025.